SC
SRPT icon

Sapient Capital’s Sarepta Therapeutics SRPT Stock Holding History

Sapient Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,540
Closed -$430K – 381
2024
Q4 		$430K Sell
3,540
-4,615
-57% -$566K 0.01% 258
2024
Q3 		$1.02M Sell
8,155
-1,845
-18% -$255K 0.02% 191
2024
Q2 		$1.58M Sell
10,000
-15
-0.1% -$1.93K 0.03% 144
2024
Q1 		$1.3M Sell
10,015
-131
-1% -$16K 0.03% 161
2023
Q4 		$978K Buy
+10,146
New +$973K 0.03% 173

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sapient Capital's SRPT Position: Q1 2025 in Review

Sapient Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 3,540 shares — an estimated $430K sold.

Sapient Capital first reported a position in SRPT in Q4 2023 and held it in 5 quarters. The position peaked at $1.58M in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Sapient Capital reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sapient Capital sold 3,540 Sarepta Therapeutics shares in Q1 2025, an estimated $430K.
  • Sapient Capital first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 5 quarters.
  • Sapient Capital's Sarepta Therapeutics position peaked at $1.58M in Q2 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Sapient Capital's 13F filing for Q1 2025, filed 15 Apr 2025.